13.2 months against 10.6: the UK has approved a new small cell lung cancer treatment
What happened
On 23 September 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a medicine called lurbinectedin, sold as Zepzelca, for adults in the UK. It is licensed for one specific situation: extensive-stage small cell lung cancer. "Extensive-stage" means the cancer has already spread beyond one lung by the time it is found. The medicine is not used on its own. It is given together with another drug, atezolizumab, as what doctors call maintenance treatment. Maintenance means treatment given after the first round of treatment has worked, to try to hold the cancer back for longer. To be eligible, a person must already have had first-line treatment with atezolizumab, carboplatin and etoposide, and their cancer must not have got worse during it. Lurbinectedin is given as a drip into a vein. The infusion takes about one hour, and the recommended dose is given once every 21 days. Treatment has to be started and supervised in a hospital or clinic by a healthcare professional. The marketing authorisation was granted to the company Pharma Mar, S.A. It was approved through a route called the International Recognition Procedure, with the European Medicines Agency acting as the reference regulator. That means the MHRA reviewed a decision another trusted regulator had already made, rather than starting from scratch.
Why this matters
Small cell lung cancer is less common than other lung cancers, but it tends to grow quickly and spread early. That is why so many people are already at the extensive stage when they are diagnosed. First treatment often works well at first. The hard part is what comes next. The cancer frequently returns, and the gap between finishing treatment and the cancer coming back can be short. That gap is exactly where maintenance treatment tries to help. The aim is not to cure, but to buy time, and to keep people feeling well for longer. There is one point worth being clear about, because it is easy to misread. An MHRA licence says a medicine is acceptably safe and works well enough to be sold in the UK. It does not automatically mean the NHS will pay for it. That is a separate decision, usually made by NICE in England, and by the Scottish Medicines Consortium in Scotland. So an approval like this is a step, not a finish line.
What the evidence actually says
The approval was based on one main study involving 483 adults with extensive-stage small cell lung cancer. People who received lurbinectedin plus atezolizumab lived for an average of 13.2 months. People who received atezolizumab alone lived for an average of 10.6 months. That is a difference of about 2.6 months on average. The study also looked at how long people went before their cancer got worse. That was an average of 5.4 months in the lurbinectedin group, compared with 2.1 months in the group given atezolizumab alone. It is important to read "average" properly. An average is what happened across a whole group. Some people did better than the average and some did worse. Nobody can promise an individual person any particular number of months. Side effects are real and worth knowing about. The most common ones reported with lurbinectedin were feeling sick, tiredness, anaemia (low red blood cells), thrombocytopenia (low platelets, which help blood clot) and neutropenia (low levels of a type of white blood cell that fights infection). Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the approval "provides a new treatment option" for this group, and that the agency "will continue to monitor its safety through the UK Yellow Card scheme". That monitoring is not a formality. The Yellow Card scheme is how suspected side effects get reported, and anyone, including patients and carers, can use it.
Qurexa perspective
Most of this treatment happens in hospital, and it should. A drip that has to be supervised by a specialist team is not something we have any part in. Where community pharmacy usually does come in is everything around it. People on cancer treatment often go home with a bag of supporting medicines: anti-sickness tablets, mouthwashes, sometimes laxatives or steroids, sometimes medicines to protect the stomach. Those are the ones that get missed. They are easy to run out of between hospital appointments, especially when someone is tired and managing several repeat prescriptions at once. That is the part we help with, and only that part. Our prescription delivery and adherence support in Lincolnshire exists so that people do not have to make an extra trip on a day when they have very little energy to spare. If that is not a problem you have, you do not need us.
Practical advice
If this news is relevant to you or someone close to you, here are some sensible next steps. Ask your oncology team directly whether this treatment applies to your situation. The licence is narrow. It covers a specific cancer type, at a specific stage, after a specific first treatment. Ask about funding as well as licensing. A useful question is: "Is this available to me on the NHS right now, and if not, what is the timetable?" Write your questions down before appointments. It is very easy to forget them in the room. Keep a simple symptom diary. Date, symptom, how bad it felt out of ten. It helps your team spot patterns, and it helps you remember what to mention. Report side effects. You can use the MHRA Yellow Card scheme yourself at yellowcard.mhra.gov.uk. You do not need to be certain the medicine caused it. Tell your pharmacist about every medicine and supplement you take, including ones bought over the counter. Cancer treatments interact with more things than people expect. Contact your team urgently if you get a temperature, shivering, or feel suddenly unwell. With low white blood cells, an infection can become serious quickly.
What to know
The MHRA approved lurbinectedin on 23 September 2026 for adults with extensive-stage small cell lung cancer, given with atezolizumab as maintenance treatment after specific first-line therapy. In the main study of 483 adults, average survival was 13.2 months with the combination against 10.6 months with atezolizumab alone, and average time before the cancer worsened was 5.4 months against 2.1 months. Common side effects include nausea, tiredness, anaemia, low platelets and low white blood cells. A UK licence is not the same as NHS funding. That decision comes separately. If this affects you, the single most useful thing you can do is ask your own oncology team what it means for your case. They know your history; a news article does not. Sources: MHRA (GOV.UK), "MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer", 23 September 2026, https://www.gov.uk/government/news/mhra-approves-lurbinectedin-for-adults-with-extensive-stage-small-cell-lung-cancer; MHRA (GOV.UK), "Marketing authorisations granted in 2026", 18 September 2026, https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; MHRA, "Yellow Card scheme", accessed 26 September 2026, https://yellowcard.mhra.gov.uk/. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never start, stop or change a cancer treatment without speaking to your specialist team.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…